Status:

TERMINATED

Effect of Oral Propranolol on mRNA Expresssion in Symptomatic Cavernous Malformation

Lead Sponsor:

St. Joseph's Hospital and Medical Center, Phoenix

Conditions:

Cerebral Cavernous Malformations

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

This is a single center, randomized, trial that will enroll twenty (n=20) patients with a diagnosis of symptomatic cavernous malformations who are planned candidates for surgical resection by one of t...

Detailed Description

This is a single center, randomized, trial that will enroll twenty (n=20) patients with a diagnosis of symptomatic cavernous malformations who are planned candidates for surgical resection by one of t...

Eligibility Criteria

Inclusion

  • Subject is at least 18-years of age.
  • Clinical and imaging diagnosis of a symptomatic Isolated cavernous malformation or Familial cavernous malformation
  • MRI Imaging Grade Type I or Type II (see Table 1)
  • Patient is considered a candidate for surgical resection of their cavernous malformation
  • Written and informed consent obtained prior to the study enrollment.
  • Negative pregnancy test at time of enrollment for women of child-bearing potential.
  • Heart rate greater than 50 beats per minute
  • Systolic blood pressure \> 90 mmHg

Exclusion

  • Subject is less than 18-years of age.
  • History of allergy to propranolol or other beta blockers.
  • Patient is already taking another beta blocker for cardiac indications.
  • History of asthma presently requiring any active treatment (oral medications or inhalers).
  • History of cardiac dysfunction (as defined by the New York Heart Association Functional Classification grade II, III or IV).
  • Heart rate \< 50 beats per minute
  • Systolic blood pressure \< 90 mmHg
  • History of diabetes and currently on any anti-hyperglycemic medication.
  • Pregnant and lactating women.

Key Trial Info

Start Date :

January 24 2018

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

February 11 2021

Estimated Enrollment :

4 Patients enrolled

Trial Details

Trial ID

NCT03474614

Start Date

January 24 2018

End Date

February 11 2021

Last Update

April 19 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Barrow Neurological Institute

Phoenix, Arizona, United States, 85013